First line Therapy by Sorafenib for Lung Metastases Patients in Renal Cell Carcinoma
Phase 2
- Conditions
- Renal cell carcinoma
- Registration Number
- JPRN-UMIN000005090
- Lead Sponsor
- Kobe University Graduate school of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have or have had thromboembolism and/or ischemic cardiac disease 2) Poorly controlled hypertension 3) Patients with serious hepatic function disorder 4) Patients who have or have had interstitial pulmonary disease 5) Pregnant or nursing patients 6) Patients being treated with other drugs for purpose of anti cancer treatment 7) Patients who may otherwise compromise subject safety in the conduct of the trial or who may compromise protocol compliance
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease Control Rate(CR+PR+SD)
- Secondary Outcome Measures
Name Time Method Response Rate(CR+PR),Progression Free Survival(PFS),Safety